Shen Qianyu, Chua Dennis Chin Wee, Chan Po Fun, Wee Hwee Lin
Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Department of Pharmacy, Ng Teng Fong General Hospital, Singapore.
PEC Innov. 2024 Sep 3;5:100342. doi: 10.1016/j.pecinn.2024.100342. eCollection 2024 Dec 15.
This study presents the development process of a heart failure (HF) medication decision aid (DA) specific to Singapore context, with the objective of promoting cost conversations.
Phase 1 was to create a DA prototype, where two HF clinicians were consulted on their input and needs. Phase 2 was pilot testing where the prototype was tested on HF patients and revised based on their feedback.
The DA is a one-page poster that compares only two classes of HF medications. It encompasses seven attributes for comparison, including route of administration, treatment duration, frequency of use, hospitalization rate, survival rate, low blood pressure probability with personalized subsidized cost being the key attribute. A total of 48 patients participated in the pilot testing with only 2 patients (4.2 %) finding the DA difficult to understand. Almost all patients agreed that the DA provided greater clarity in the medication options.
By integrating the needs of both clinicians and patients and conducting user testing, we developed a novel HF medication DA. Patients found the tool easy to understand and acceptable.
This innovative DA aims to improve cost conversations by providing tailored, concise, and locally relevant information for efficient use.
本研究展示了一款针对新加坡背景的心力衰竭（HF）药物决策辅助工具（DA）的开发过程，旨在促进关于成本的讨论。
第一阶段是创建一个DA原型，向两名HF临床医生咨询他们的意见和需求。第二阶段是进行试点测试，在HF患者身上测试该原型，并根据他们的反馈进行修订。
该DA是一张单页海报，仅比较两类HF药物。它包含七个比较属性，包括给药途径、治疗持续时间、使用频率、住院率、生存率、低血压概率，其中个性化补贴成本是关键属性。共有48名患者参与了试点测试，只有2名患者（4.2%）认为该DA难以理解。几乎所有患者都认为该DA使药物选择更加清晰。
通过整合临床医生和患者的需求并进行用户测试，我们开发了一种新型的HF药物DA。患者发现该工具易于理解且可以接受。
这款创新的DA旨在通过提供量身定制、简洁且与当地相关的信息以实现高效使用，从而改善关于成本的讨论。
